SIGA v. PharmAthene: Delaware Supreme Court Grants Expectation Damages to Remedy Breach of Obligation to Negotiate in Good Faith | Practical Law

SIGA v. PharmAthene: Delaware Supreme Court Grants Expectation Damages to Remedy Breach of Obligation to Negotiate in Good Faith | Practical Law

The Supreme Court of the State of Delaware remanded SIGA Technologies v. PharmAthene back to the Delaware Court of Chancery after clarifying that a plaintiff may be awarded contract expectation damages for a breach of an obligation, contained in a contract, to negotiate in good faith.

SIGA v. PharmAthene: Delaware Supreme Court Grants Expectation Damages to Remedy Breach of Obligation to Negotiate in Good Faith

by PLC Corporate & Securities
Published on 05 Jun 2013Delaware
The Supreme Court of the State of Delaware remanded SIGA Technologies v. PharmAthene back to the Delaware Court of Chancery after clarifying that a plaintiff may be awarded contract expectation damages for a breach of an obligation, contained in a contract, to negotiate in good faith.
On May 24, 2013, the Supreme Court of the State of Delaware issued an opinion in SIGA Technologies v. PharmAthene, affirming in part and reversing in part the Delaware Court of Chancery's September 2011 decision. The Supreme Court affirmed that an obligation to negotiate in good faith the terms agreed to in a term sheet is enforceable and held that the non-breaching party is entitled to expectation damages if both:
  • The obligation to negotiate is contained in a fully integrated contract.
  • The parties would have reached an agreement on the terms in the term sheet but for the defendant's bad-faith negotiation.

Background

Both SIGA and PharmAthene are Delaware corporations involved in biodefense research and development. In late 2005, SIGA was facing financial difficulties and began considering a collaboration with PharmAthene. PharmAthene wanted to merge with SIGA, but SIGA sought instead to enter into a license agreement (which would give it an immediate infusion of cash) rather than discussing a merger. The parties began exchanging draft term sheets and a nearly final version was presented to PharmAthene's board. The board did not sign the term sheet and the minutes of its meeting did not reflect whether it approved the term sheet. However, a clean copy of the license-agreement term sheet incorporating the last of SIGA's comments on the license was produced. This copy was not signed and included a footer on each page reading "non-binding terms."
Shortly after the completion of the term sheet, PharmAthene decided that it preferred a merger with SIGA to a license agreement. The parties began simultaneously negotiating a merger agreement and a license agreement that would be entered into in case the merger did not close. After entering into an interim bridge-loan agreement containing a negotiation obligation, the parties entered into a merger agreement that similarly obligated the parties to negotiate a definitive license agreement in good faith in accordance with the terms of the license-agreement term sheet if the merger agreement were to be terminated before closing.
Soon after entering into the merger agreement, SIGA's prospects as an independent corporation improved and its board decided to terminate the merger agreement. Although SIGA recognized that it had an obligation to negotiate a license agreement, it presented PharmAthene with a draft license agreement that contained significantly different terms from those included in the term sheet. SIGA, which disputed that the term sheet was binding because of the "non-binding terms" footer, eventually issued an ultimatum that it would stop negotiations if PharmAthene did not agree to negotiate the license agreement without preconditions based on the term sheet.
PharmAthene filed suit in the Court of Chancery, asserting claims of breach of contract, promissory estoppel and unjust enrichment. The Court of Chancery found for PharmAthene, holding that SIGA had breached its contractual obligation in the merger agreement to negotiate in good faith and was liable under the doctrine of promissory estoppel. The Court of Chancery granted PharmAthene equitable damages, as well as attorneys' fees and costs. SIGA appealed the Court of Chancery's holding.

Outcome

Obligation to Negotiate in Good Faith

The Supreme Court affirmed the Court of Chancery's ruling that SIGA had breached its obligation to negotiate in good faith under both the bridge loan and merger agreements. In rejecting SIGA's argument that a non-binding term sheet cannot form the basis for an enforceable obligation to negotiate, the Supreme Court explicitly reaffirmed its holding in Titan Investment Fund II, LP v. Freedom Mortgage Corp. that an express contractual obligation to negotiate in good faith is binding on the contracting parties. The Supreme Court also agreed with the Court of Chancery that the phrase in the bridge loan and merger agreements "in accordance with the terms set forth" meant that the parties had a duty to negotiate a license agreement on terms substantially similar to those found in the term sheet, even though the term sheet was not, in and of itself, a binding contract. In addition, the Supreme Court rejected SIGA's argument that holding it to this obligation would introduce uncertainty and litigation risk. As it explained, acting in "bad faith" implies a "conscious doing of a wrong" with a "dishonest purpose" or "ill will," not merely acting negligently or with bad judgment. This standard of conduct should not introduce a great deal of uncertainty into negotiations.
Because SIGA presented terms radically different from the terms negotiated in the term sheet, and did so in bad faith, the Supreme Court affirmed the Court of Chancery's finding that SIGA had breached its obligation to negotiate in good faith.

Remedy Under Promissory Estoppel

The Supreme Court reversed the Court of Chancery's ruling that SIGA was liable under the promissory estoppel doctrine, stating that promissory estoppel does not apply if an enforceable contract governs the promise to negotiate in good faith. Instead, a court must look to the contract to determine the remedy for a breach of the duty to negotiate in good faith. Because the Supreme Court found that the duty to negotiate in good faith was expressly incorporated into both the bridge loan and merger agreements, the contract would govern the remedy.

Remedy Under Contract

The Supreme Court noted that its decision in Titan Investment left open the question of whether a judge could grant expectation damages when a factual finding is made that an agreement would have been reached but for the defendant's breach. The Court of Chancery had noted that there was no consensus in Delaware or in other jurisdictions over whether a plaintiff could recover expectation damages or only reliance damages. While noting that it must apply Delaware law, the Supreme Court looked to other federal courts' interpretations of New York law, which recognizes two types of binding preliminary agreements:
  • Type I agreements. Complete meetings of the mind that bind both sides to the ultimate contractual goal, even though the parties contemplate executing a more formal agreement.
  • Type II agreements. Reflecting agreement only on major terms and therefore binding only to a certain degree, but leaving other terms open. These agreements do not bind the parties to the ultimate contractual goal, but do bind them to negotiate the open issues in good faith.
The license-agreement term sheet at issue in this case would be considered a Type II agreement. The Supreme Court concluded that a plaintiff is entitled to recover contract expectation damages if:
  • A party has a Type II preliminary agreement to negotiate in good faith.
  • A factual finding is made that an agreement would have been reached but for the defendant's breach.
Delaware courts had not previously recognized that a plaintiff could recover expectation damages under Type II agreements. Key to the Supreme Court's ruling though is that a plaintiff must be able to prove damages with reasonable certainty, requiring therefore that the Type II agreement encompass enough major terms to determine what the contract would have looked like but for the breach.
The Supreme Court remanded the case to the Court of Chancery for reconsideration of the damages award in light of the Supreme Court's clarification that "Delaware recognizes Type II agreements and permits a plaintiff to recover expectation damages."

Practical Implications

This case is the first time that the Supreme Court has clarified that a plaintiff may recover contract expectation damages if the defendant breaches a duty contained in a contract to negotiate in good faith and the terms are sufficiently certain that an agreement would have been reached but for the defendant's breach. Once the obligation to negotiate on the basis of a term sheet is contained in a fully integrated contract, the fact that the term sheet, in and of itself, is non-binding is of no consequence. It is important to note, however, that the Supreme Court's clarification presupposes that the plaintiff can prove damages with reasonable certainty. Therefore, the parties should be careful to make sure that key terms are addressed in the agreement to ensure the availability of contract expectation damages in case of one party's breach.